Skip to main content

Advertisement

SpringerLink
Log in

Is RAD51 135G>C polymorphism really associated with breast cancer in general population? Biased design and results lead to inappropriate conclusion

  • Letter to the Editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gao LB, Pan XM, Li LJ, Liang WB, Zhu Y, Zhang LS, Wei YG, Tang M, Zhang L (2011) RAD51 135G/C polymorphism and breast cancer risk: a meta-analysis from 21 studies. Breast Cancer Res Treat 125:827–835. doi:10.1007/s10549-10010-10995-10548

    Article  PubMed  CAS  Google Scholar 

  2. Sun H, Bai J, Chen F, Jin Y, Yu Y, Jin L, Fu S (2011) RAD51 G135C polymorphism is associated with breast cancer susceptibility: a meta-analysis involving 22, 399 subjects. Breast Cancer Res Treat 125:157–161

    Article  PubMed  Google Scholar 

  3. Wang Z, Dong H, Fu Y, Ding H (2010) RAD51 135G>C polymorphism contributes to breast cancer susceptibility: a meta-analysis involving 26, 444 subjects. Breast Cancer Res Treat 124:765–769

    Article  PubMed  CAS  Google Scholar 

  4. Yu KD, Yang C, Fan L, Chen AX, Shao ZM (2010) RAD51 135G>C does not modify breast cancer risk in non-BRCA1/2 mutation carriers: evidence from a meta-analysis of 12 studies. Breast Cancer Res Treat (in press). doi: 10.1007/s10549-10010-10937-10545

  5. Zhou GW, Hu J, Peng XD, Li Q (2011) RAD51 135G>C polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 125:529–535

    Article  PubMed  CAS  Google Scholar 

  6. Lu PH, Chen MB, Shen W, Li C, Wu MY, Tao GQ (2011) New conflicting results obtained in the subgroup analysis of RAD51 135G>C polymorphism and breast cancer risk. Breast Cancer Res Treat. 126:265–266. doi:10.1007/s10549-10010-11267-10543

    Article  PubMed  Google Scholar 

  7. Yu KD, Chen AX, Qiu LX, Fan L, Yang C, Shao ZM (2010) XRCC2 Arg188His polymorphism is not directly associated with breast cancer risk: evidence from 37, 369 subjects. Breast Cancer Res Treat 123:219–225

    Article  PubMed  CAS  Google Scholar 

  8. Yu KD, Chen AX, Shao ZM (2010) No association between a progesterone receptor gene promoter polymorphism (+331G>A) and breast cancer risk in Caucasian women: evidence from a literature-based meta-analysis. Breast Cancer Res Treat 122:853–858

    Article  PubMed  CAS  Google Scholar 

  9. Qiu LX, Mao C, Yao L, Yu KD, Zhan P, Chen B, Liu HG, Yuan H, Zhang J, Xue K, Hu XC (2010) XRCC3 5′-UTR and IVS5–14 polymorphisms and breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat 122:489–493

    Article  PubMed  CAS  Google Scholar 

  10. Yu KD, Di GH, Fan L, Chen AX, Yang C, Shao ZM (2010) Lack of an association between a functional polymorphism in the interleukin-6 gene promoter and breast cancer risk: a meta-analysis involving 25, 703 subjects. Breast Cancer Res Treat 122:483–488

    Article  PubMed  CAS  Google Scholar 

  11. Yu KD, Chen AX, Yang C, Qiu LX, Fan L, Xu WH, Shao ZM (2010) Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 122:251–257

    Article  PubMed  CAS  Google Scholar 

  12. Walsh T, King MC (2007) Ten genes for inherited breast cancer. Cancer Cell 11:103–105

    Article  PubMed  CAS  Google Scholar 

  13. Lymberis SC, Parhar PK, Katsoulakis E, Formenti SC (2004) Pharmacogenomics and breast cancer. Pharmacogenomics 5:31–55

    Article  PubMed  CAS  Google Scholar 

  14. Li WF, Hu Z, Rao NY, Song CG, Zhang B, Cao MZ, Su FX, Wang YS, He PQ, Di GH, Shen KW, Wu J, Lu JS, Luo JM, Liu XY, Zhou J, Wang L, Zhao L, Liu YB, Yuan WT, Yang L, Shen ZZ, Huang W, Shao ZM (2008) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat 110:99–109

    Article  PubMed  CAS  Google Scholar 

  15. Antoniou AC, Sinilnikova OM, Simard J, Leone M, Dumont M, Neuhausen SL, Struewing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ, Coupier I, Belotti M, Lasset C, Bonadona V, Bignon YJ, Rebbeck TR, Wagner T, Lynch HT, Domchek SM, Nathanson KL, Garber JE, Weitzel J, Narod SA, Tomlinson G, Olopade OI, Godwin A, Isaacs C, Jakubowska A, Lubinski J, Gronwald J, Gorski B, Byrski T, Huzarski T, Peock S, Cook M, Baynes C, Murray A, Rogers M, Daly PA, Dorkins H, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Niederacher D, Deissler H, Spurdle AB, Chen X, Waddell N, Cloonan N, Kirchhoff T, Offit K, Friedman E, Kaufmann B, Laitman Y, Galore G, Rennert G, Lejbkowicz F, Raskin L, Andrulis IL, Ilyushik E, Ozcelik H, Devilee P, Vreeswijk MP, Greene MH, Prindiville SA, Osorio A, Benitez J, Zikan M, Szabo CI, Kilpivaara O, Nevanlinna H, Hamann U, Durocher F, Arason A, Couch FJ, Easton DF, Chenevix-Trench G (2007) RAD51 135G–>C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 81:1186–1200

    Article  PubMed  CAS  Google Scholar 

References for Rebuttal letter

  1. Yu KD, Yang C, Fan L, Chen AX, Shao ZM (2010) RAD51 135G>C does not modify breast cancer risk in non-BRCA1/2 mutation carriers: evidence from a meta-analysis of 12 studies. Breast Cancer Res Treat (in press)

  2. Sun H, Bai J, Chen F, Jin Y, Yu Y, Jin L, Fu S (2011) RAD51 G135C polymorphism is associated with breast cancer susceptibility: a meta-analysis involving 22, 399 subjects. Breast Cancer Res Treat 125:157–161

    Article  PubMed  Google Scholar 

  3. Wang Z, Dong H, Fu Y, Ding H (2010) RAD51 135G>C polymorphism contributes to breast cancer susceptibility: a meta-analysis involving 26, 444 subjects. Breast Cancer Res Treat 124:765–769

    Article  PubMed  CAS  Google Scholar 

  4. Zhou GW, Hu J, Peng XD, Li Q (2011) RAD51 135G>C polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 125:529–535

    Article  PubMed  CAS  Google Scholar 

  5. Gao LB, Pan XM, Li LJ, Liang WB, Zhu Y, Zhang LS, Wei YG, Tang M, Zhang L (2011) RAD51 135G/C polymorphism and breast cancer risk: a meta-analysis from 21 studies. Breast Cancer Res Treat 125:827–835

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This research is supported by the 2009 Youth Foundation of Shanghai Public Health Bureau, the 2009 Youth Foundation of Shanghai Medical College, the Shanghai United Developing Technology Project of Municipal Hospitals (SHDC12010116), and the National Natural Science Foundation of China (30971143, 30972936, 81001169).

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Breast Surgery, Cancer Hospital/Cancer Institute, Fudan University, 399 Ling-Ling Road, Shanghai, 200032, People’s Republic of China

    Ke-Da Yu, Bin Li, Ying Zhou & Zhi-Ming Shao

  2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China

    Ke-Da Yu & Zhi-Ming Shao

  3. Department of Nurse, Cancer Institute and Cancer Center, Fudan University, Shanghai, People’s Republic of China

    Bin Li & Ying Zhou

  4. Institutes of Biomedical Science, Fudan University, Shanghai, People’s Republic of China

    Zhi-Ming Shao

Authors
  1. Ke-Da Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ying Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhi-Ming Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhi-Ming Shao.

Additional information

Ke-Da Yu, Bin Li, and Ying Zhou have contributed equally to this study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yu, KD., Li, B., Zhou, Y. et al. Is RAD51 135G>C polymorphism really associated with breast cancer in general population? Biased design and results lead to inappropriate conclusion. Breast Cancer Res Treat 128, 297–300 (2011). https://doi.org/10.1007/s10549-011-1402-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-011-1402-9

Keywords

Search

Navigation